Status:
COMPLETED
NAD-supplementation in Drug naïve Parkinson's Disease
Lead Sponsor:
Haukeland University Hospital
Conditions:
Parkinson Disease
Neurodegenerative Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
1. Primary objective: Determine if NR has an impact on the neurometabolic profile of patients with PD as measured by \[18F\]Fluorodeoxyglucose (FDG)-positron emission tomography (FDG-PET). 2. Secondar...
Detailed Description
Individuals with PD (n=30) will be recruited starting 14/02/2019 from the department of Neurology, Haukeland University Hospital. Only newly diagnosed and drug naïve PD patients are eligible for inclu...
Eligibility Criteria
Inclusion
- Newly diagnosed with PD
- Drug naïve with respect to dopaminergic treatment
- Have a clinical diagnosis of idiopathic PD according to the MDS clinical diagnostic criteria for PD
Exclusion
- \[¹²³I\]FP-CIT single photon emission CT (DaTscan) does not show nigrostriatal degeneration.
- Magnetic resonance imaging (MRI) suggestive of atypical parkinsonsism.
- Dementia or other neurological disorder at baseline visit
- Metabolic, neoplastic, or other physically or mentally debilitating disorder at baseline visit
Key Trial Info
Start Date :
March 9 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 10 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03816020
Start Date
March 9 2019
End Date
February 10 2020
Last Update
February 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haukeland University Hospital
Bergen, Hordaland, Norway, 5021